Vaccination with ISG15 confers regression of HPV-associated tumor burden in mice, providing new insight into the immunomodulatory properties of ISG15 and its potential to serve as an effective immune adjuvant in cancer therapies214. This evidence concerns the gene ISG15 and neoplasm.